Kelly C. Goldsmith
MD
Dr. Goldsmith's research focuses on defining molecular mechanisms of chemotherapy resistance in neuroblastoma in order to translate novel therapeutics into early phase clinical trials.
Specialty
Dr. Goldsmith specializes in the treatment of neuroblastoma, Wilms tumor and other renal tumors of childhood.
Titles and Roles
- Professor, Department of Pediatrics
- Emory University School of Medicine
- Co-Leader, Discovery & Developmental Therapeutics Program
- Winship Cancer Institute of Emory University
- Director Neuroblastoma/MIBG Therapy Program
- Aflac Cancer and Blood Disorders Center
- Pediatric Oncologist
- Pediatric Oncology
- Research Program
- Discovery and Developmental Therapeutics
Biography
Kelly Goldsmith, MD, is Professor of Pediatrics at Emory University School of Medicine. Dr. Goldsmith serves as co-leader of the Discovery and Developmental Therapeutics Research Program at Winship Cancer Institute of Emory University, as director Neuroblastoma/MIBG Therapy Program and as clinical director, Aflac Precision Medicine Program at the Aflac Cancer and Blood Disorders Center of Children's Healthcare of Atlanta. She is board certified in Pediatric Hematology and Oncology by the American Board of Pediatrics, and specializes in the treatment of neuroblastoma, Wilms tumor and other renal tumors of childhood.
Dr. Goldsmith holds professional memberships with several scientific societies including American Society of Pediatric Hematology and Oncology, American Association for Cancer Research, American Society of Clinical Oncology, and Children's Oncology Group.
Education
Dr. Goldsmith received her Medical Degree from the University of Alabama School of Medicine in Birmingham, AL. She completed a residency in pediatrics and a fellowship in pediatric hematology and oncology at The Children's Hospital of Philadelphia in Philadelphia, PA.
Research
Dr. Goldsmith's laboratory investigates the molecular mechanisms of chemotherapy resistance in pediatric neuroblastoma, focusing on experimental therapeutics that restore therapy sensitivity. Her research expertise is in apoptosis deregulation in cancer, the Bcl-2 family, and neurodevelopmental genes that play a role in therapy resistance. Her translational research provided the concept behind a first in pediatrics Phase I trial of simvastatin in combination with chemotherapy for recurrent solid/CNS tumors of childhood. She is co-chair of a NANT Precision Medicine Study for recurrent neuroblastoma and chair of the AflacST1402 trial. Dr. Goldsmith rounds out her bench to bedside personality as the clinical director of our Refractory and Recurrent Neuroblastoma Program where she and her team work to match a relapsed patient with the appropriate therapy for their recurrent disease.
Below is a listing of current federal grants for the above principal investigator.
GrantNumber Title
Publications
Publications Publication Date
Awards
Dr. Goldsmith's has received several awards and honors including:
- American Cancer Society Mentored Research Scholars Awardee, 2008
- ASCO Young Investigator Award, 2005
- Caitlin Robb Foundation Award, 2004
- Italian Neuroblastoma Foundation Award—Advances in Neuroblastoma Research Meeting, Genoa, Italy, 2004